Bioxcel therapeutics announces presentations on serenity i & ii at the 2021 american psychiatric association annual meeting

New haven, conn., april 26, 2021 (globe newswire) -- bioxcel therapeutics, inc. ("bioxcel" or the "company") (nasdaq: btai), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that data from its two pivotal phase 3 trials (serenity i & ii) of bxcl501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders i and ii will be presented at the upcoming american psychiatric association (“apa”) annual meeting. the meeting will be held virtually on may 1-3, 2021.
BTAI Ratings Summary
BTAI Quant Ranking